MASLD (metabolic dysfunction–associated steatotic liver disease) is fat build-up in the liver occurring alongside metabolic risk factors such as excess weight, type 2 diabetes, high blood pressure or abnormal lipids. It ranges from simple fat (steatosis) through inflammation (MASH) to scarring (fibrosis) and, rarely, cirrhosis — and the amount of fat is not the same as the amount of scarring.
What MASLD actually means
MASLD stands for Metabolic dysfunction–Associated Steatotic Liver Disease. In plain parts:
- Steatotic — the liver is storing fat (steatosis).
- Metabolic dysfunction–associated — that fat sits alongside at least one cardiometabolic risk factor: excess weight or central adiposity, prediabetes or type 2 diabetes, high blood pressure, high triglycerides, or low HDL.
MASLD is the liver's readout of whole-body metabolic health. It is not a rare or exotic diagnosis: it is now the most common chronic liver condition in the world, affecting roughly a quarter to a third of adults and a majority of people with type 2 diabetes or significant obesity. Most fatty livers are low-risk, a meaningful minority are not, and the label "fatty liver" alone does not distinguish between them. → Who Should Be Evaluated?
The words changed: NAFLD → MASLD, NASH → MASH
A diagnosis of NAFLD or NASH given years ago refers to the same disease under an older name. In 2023 an international consensus renamed the condition:
- NAFLD → MASLD (Metabolic dysfunction–Associated Steatotic Liver Disease). The old name, "non-alcoholic fatty liver disease," defined the condition by what it was not; the new one defines it by what it is, a metabolic disease.
- NASH → MASH (Metabolic dysfunction–Associated Steatohepatitis) — the inflammatory, injurious form.
- MetALD, a new overlap term, describes metabolic fatty liver plus meaningful alcohol intake, recognising that many people have both drivers rather than one.
The rename removed a stigmatising "alcoholic" framing and put the metabolic cause in the name. The current terms are used throughout this site, and are identical in substance to the conditions formerly called NAFLD and NASH.
How fat gets into the liver — insulin resistance and visceral fat
MASLD is not primarily a problem of eating fatty food. It is a problem of insulin resistance and of where the body stores energy.
- Visceral fat — fat packed around the abdominal organs — is metabolically active and releases fatty acids and inflammatory signals into the portal blood that drains straight to the liver. This is why central adiposity (waist size) tracks with liver fat better than overall weight does, and why a person of normal weight carrying visceral fat can develop lean MASLD.
- Insulin resistance means muscle and fat tissue respond poorly to insulin, so the body compensates with higher insulin levels. High insulin drives the liver to make new fat (de novo lipogenesis) and impairs its ability to export and burn fat.
- Hepatic insulin resistance is the liver's own version of the problem. A fat-laden liver handles insulin poorly, so it keeps releasing glucose when it should not, which raises blood sugar and feeds the cycle.
MASLD, type 2 diabetes and cardiovascular disease therefore grow from the same soil, and treating the liver in isolation misses most of the problem. → Obesity & Insulin Resistance · MASLD & Cardiovascular Risk
The spectrum — four different things
MASLD is not one condition but a spectrum, and the stages are not interchangeable.
- Steatosis (fat). Fat stored in liver cells. Common, usually low-risk on its own, and most people with it never progress.
- MASH (inflammation and injury). Fat plus inflammation and damage to liver cells — steatohepatitis. This is the form that actively drives scarring, and it cannot be diagnosed from the amount of fat alone.
- Fibrosis (scarring). The liver's scar-tissue response to ongoing injury. Fibrosis stage is the strongest predictor of serious liver outcomes — more than fat, more than enzymes. It is staged F0–F4.
- Cirrhosis (F4). Advanced scarring that distorts the liver's architecture, raising the risk of liver failure, portal hypertension and hepatocellular carcinoma (HCC, liver cancer), and able to develop in someone who feels well.
Fat in the liver and fibrosis in the liver are separate findings. One person can have a strikingly fatty liver with almost no scarring; another can have only modestly abnormal tests alongside clinically important fibrosis. "You have a fatty liver" is therefore a starting point rather than an answer, and the whole diagnostic pathway exists to separate finding fat from finding risk. → The WeightExperts Diagnostic Approach
Fibrosis stages F0–F4
Fibrosis is described in five stages. Roughly:
| Stage | What it describes |
|---|---|
| F0 | No fibrosis |
| F1 | Mild fibrosis (limited scarring) |
| F2 | Moderate ("significant") fibrosis — scarring extends further |
| F3 | Advanced ("bridging") fibrosis — bands of scar link regions of the liver |
| F4 | Cirrhosis — advanced scarring distorting liver architecture |
The clinically important threshold is around F2 and above, the "at-risk" range, because that is where the risk of progression and complications rises and where medications now carry specific indications. F2–F3 is the range for which the first MASH medications are approved. Staging is a way of matching attention to risk rather than a judgment about the person. → MASH Medications
Where cirrhosis and liver cancer fit
Only a minority of people with MASLD progress through MASH and fibrosis to cirrhosis. Because the condition is so common, however, MASLD is now a leading and rising cause of cirrhosis, liver transplantation and hepatocellular carcinoma worldwide. Cirrhosis is largely irreversible, though its complications can still be reduced, and it warrants specialist surveillance, including for HCC. Identifying and treating disease before that stage, when fat and even fibrosis are more reversible, is what risk stratification is for. → Fatty Liver & Weight Loss
Why "fat" and "fibrosis" are measured differently
Because fat and scarring are different things, they are measured with different tools — a distinction that patients, and sometimes reports, blur:
- Liver fat is estimated by ultrasound, CT, MRI, MRI-PDFF (a precise fat-fraction measurement) and UDFF (ultrasound-derived fat fraction) on the ultrasound used for elastography.
- Liver fibrosis is estimated by the FIB-4 blood score, by liver stiffness on elastography (ultrasound shear-wave elastography or MRE), and, as a reference standard, by biopsy.
A single elastography exam can report both: a UDFF percentage for fat and a kPa stiffness number for fibrosis. They answer different questions, and confusing how much fat with how much scar is the most common misreading in this area. → Elastography & Liver Fat · FIB-4 Explained
What the evidence says: what MASLD is
- What we know: MASLD is metabolic fatty liver disease on a spectrum from steatosis through MASH and fibrosis to cirrhosis; fibrosis stage rather than fat amount most predicts outcomes; insulin resistance and visceral fat are central drivers.
- What we think: naming the metabolic cause (MASLD/MASH) reflects the biology better and should push care toward treating the whole metabolic picture rather than the liver alone.
- What we don't know: exactly who among people with simple steatosis will progress, and how much of the risk is genetic rather than metabolic in any given person.
- What patients should do: establish which part of the spectrum a diagnosis refers to, get risk-stratified rather than only labelled, and address the underlying metabolic drivers. → Who Should Be Evaluated?
In our practice that means a liver assessment reports fat and fibrosis separately, and the metabolic drivers behind both are treated together.
Questions patients ask
Is MASLD the same as fatty liver?
Essentially yes — MASLD is the current medical name for metabolic fatty liver disease. It specifies that the fat is linked to metabolic risk factors. Grade A 🟢
What's the difference between MASLD and MASH?
MASLD is the umbrella term, fat with or without inflammation. MASH is the subset with inflammation and cell injury that can drive scarring. Most MASLD is not MASH. Grade A 🟢
Why was NAFLD renamed to MASLD?
A 2023 consensus renamed NAFLD→MASLD and NASH→MASH to reduce stigma and name the metabolic cause instead of defining the disease as "non-alcoholic." The condition itself is unchanged. Grade A 🟢
Is fat in the liver the same as scarring?
No, and this is the central point. A very fatty liver can carry little scarring, and modest fat can accompany important fibrosis. Fibrosis is what most predicts serious outcomes. Grade A 🟢 → Diagnostic Approach
Can thin people have MASLD?
Yes. "Lean MASLD" occurs, usually with visceral fat, insulin resistance or genetic factors, so a normal weight does not exclude it. Grade B 🟡
Is MASLD reversible?
Often, earlier in the spectrum — liver fat and MASH inflammation respond well to metabolic improvement. Fibrosis improves more slowly, and cirrhosis is largely irreversible. Earlier is more reversible. Grade A 🟢 → Fatty Liver & Weight Loss
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: AASLD Practice Guidance on MASLD (2023) and subsequent semaglutide/MASH labeling update; EASL–EASD–EASO clinical practice guidance; MASLD/MASH nomenclature consensus (2023). Educational; not individualized advice.
